← Leaderboards
William Pao
Sloan-Kettering Institute For Cancer Res
$4,438,803
Attributed
$5,403,243
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $702K · FY2005–16$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$5,403,243 · 4
By mechanism
P01$2,928,563 · 2
R01$1,999,102 · 1
K08$475,578 · 1
Top collaborators
- Marc Ladanyi5 shared
Most similar at Sloan-Kettering Institute For Cancer Res
Same institution · by research overlap
- Ronald P Dematteo$17,312,014
- Peter Besmer$10,009,274
- Marc Ladanyi$28,443,479
- Robert I Benezra$12,794,451
- Dinshaw J Patel$22,114,307
Others in their field
Top investigators on “Mutation”
- Richard A Gibbs · Baylor College Of Medicine$276,143,183
- David Heimbrook · Leidos Biomedical Research, Inc.$175,834,894
- Randall J Bateman · Washington University$154,391,630
- Eric Martin McDade · Washington University$96,219,353
- Stacey Gabriel · Massachusetts Institute Of Technology$95,141,374
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$93,475,056
Research focus
MutationMolecularMutantNeoplastic CellMalignant Neoplasm Of LungEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorExonsBiochemicalEpidermal Growth Factor ReceptorDrug-SensitiveResistanceErlotinibResponseGefitinibPhosphotransferasesMouse ModelTumorAffectCancer CellSiteInsightProgressive DiseaseGrantBase
Grant awards (21)
Mechanisms and Modulators of Sensitivity and Resistance to EGFR Inhibitors in Lu$390,070
P01 · FY2016 · CA · contact PI
Mechanisms and Modulators of Sensitivity and Resistance to EGFR Inhibitors in Lu$390,070
P01 · FY2015 · CA · contact PI
Mechanisms and Modulators of Sensitivity and Resistance to EGFR Inhibitors in Lu$382,626
P01 · FY2014 · CA · contact PI
Mechanisms and Modulators of Sensitivity and Resistance to EGFR Inhibitors in Lu$366,666
P01 · FY2013 · CA · contact PI
Overcoming acquired resistance to EGFR inhibitors in lung cancer$284,587
R01 · FY2013 · CA · contact PI
Mechanisms and Modulators of Sensitivity and Resistance to EGFR Inhibitors in Lu$399,448
P01 · FY2012 · CA · contact PI
Overcoming acquired resistance to EGFR inhibitors in lung cancer$302,574
R01 · FY2012 · CA · contact PI
Overcoming acquired resistance to EGFR inhibitors in lung cancer$258,204
R01 · FY2011 · CA · contact PI
EGFR Kinase Inhibitor-Persistent EGFR-Mutant Lung Adenocarcinoma$217,539
P01 · FY2011 · CA · contact PI
Overcoming acquired resistance to EGFR inhibitors in lung cancer$265,050
R01 · FY2010 · CA · contact PI
EGFR Kinase Inhibitor-Persistent EGFR-Mutant Lung Adenocarcinoma$225,235
P01 · FY2010 · CA · contact PI
Overcoming acquired resistance to EGFR inhibitors in lung cancer$264,195
R01 · FY2009 · CA · contact PI
EGFR Kinase Inhibitor-Persistent EGFR-Mutant Lung Adenocarcinoma$220,515
P01 · FY2009 · CA · contact PI
Overcoming acquired resistance to EGFR inhibitors in lung cancer$312,246
R01 · FY2008 · CA · contact PI
EGFR Kinase Inhibitor-Persistent EGFR-Mutant Lung Adenocarcinoma$185,397
P01 · FY2008 · CA · contact PI
Elucidating Mechanisms of Lung Tumor Regression$101,596
K08 · FY2008 · CA · contact PI
Overcoming acquired resistance to EGFR inhibitors in lung cancer$312,246
R01 · FY2007 · CA · contact PI
EGFR Kinase Inhibitor-Persistent EGFR-Mutant Lung Adenocarcinoma$150,997
P01 · FY2007 · CA · contact PI
Elucidating Mechanisms of Lung Tumor Regression$101,596
K08 · FY2007 · CA · contact PI
Elucidating Mechanisms of Lung Tumor Regression$136,193
K08 · FY2006 · CA · contact PI
Elucidating Mechanisms of Lung Tumor Regression$136,193
K08 · FY2005 · CA